HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
CCCR Research Studies
1 - 10 of 19
The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
The purpose of this study is to find out if alpelisib (BYL719; the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease.
This study involves taking a study drug called BA3011. The overall goal of this study is to see is BA3011is a possible treatment for patients with sarcoma.
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.
The Department of Genomic Diagnostics is interested in studying genetic/molecular testing results from patients who are diagnosed with cancer as confirmed by genetic testing done at CHOP.
This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen.
The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.
The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.
This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.